Menu Search
Equities

Invent Medic Sweden AB

IMS:AKT

Invent Medic Sweden AB

Actions
  • Price (SEK)0.332
  • Today's Change0.02 / 6.41%
  • Shares traded603.00
  • 1 Year change-62.04%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Invent Medic Sweden AB grew revenues 115.97% from 3.11m to 6.71m while net income improved from a loss of 11.98m to a smaller loss of 8.53m.
Gross margin77.43%
Net profit margin-119.45%
Operating margin-110.56%
Return on assets-72.67%
Return on equity-164.59%
Return on investment-133.97%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Invent Medic Sweden AB fell by 1.51m. Cash Flow from Financing totalled 9.70m or 144.55% of revenues. In addition the company used 6.74m for operations while cash used for investing totalled 4.46m.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.0566
Tangible book value per share-0.0012
More ▼

Balance sheet in SEKView more

Invent Medic Sweden AB has a Debt to Total Capital ratio of 27.03%, a higher figure than the previous year's 17.80%.
Current ratio0.4932
Quick ratio0.3951
Total debt/total equity0.3704
Total debt/total capital0.2703
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.